A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC).
Year: 2025
Type: conference-abstract
Study design: Study Protocol
Source: Journal of Clinical Oncology
Authors: Angeles Alvarez Secord, Elizabeth Katherine Lee, Michael J. Sundborg, Destin Black, David Starks, Edwin A. Alvarez, David R. Spigel, Noelle Cloven, Lynne M. Knowles, Anton Melnyk, William Winter, Michael McCollum, Ibrahima Soumaoro, Yan Liu, Christian Marth, GOG-3107 Investigators; ENGOT-OV86 Investigators
Institutions: Duke University, Duke Cancer Institute, Dana-Farber Cancer Institute, FirstHealth of the Carolinas, Gynecologic Oncology Associates, Avera Health, UCSF Helen Diller Family Comprehensive Cancer Center, Sarah Cannon, Texas Oncology, Virginia Oncology Associates, Genmab (United States), Innsbruck Medical University
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410815516